- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
KKR / IMPILO / IMMEDICA
M.11609
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Disclaimer :
The Competition DG makes the information provided by the notifying parties in section 4 of Short Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.
SECTION 4
Description of the concentration
On 30 July 2024, the European Commission received notification of a proposed concentration pursuant to Article 4 of the EUMR by which KKR & Co. Inc. (together with its subsidiaries, “KKR”) and Impilo AB (or one of its affiliates) ("Impilo” and together with KKR the “Parties”) intend to acquire indirect joint control, within the meaning of Article 3(1)(b) and Article 3(4) of the EUMR, of Immedica Pharma Holding AB (together with its subsidiaries, “Immedica Pharma AB”) (the “Transaction”), pursuant to a Share Purchase Agreement executed on 20 April 2024.
Impilo currently has sole control of Immedica Pharma AB and as such the Transaction from Impilo’s perspective entails the acquisition by funds, vehicles and/or accounts advised and managed by KKR of a 40 – 49% interest in Immedica Pharma AB (noting final percentages to be confirmed pre-closing).
The concentration will be accomplished by way of purchase of shares.
KKR is a global investment firm that offers alternative asset management as well as capital markets and insurance solutions.
Impilo is a Nordic investment company with a sole focus on investments in companies operating in the pharmaceutical, medtech, specialist pharma services or other healthcare and related services industries.
Immedica Pharma AB is a pharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care products. Immedica Pharma AB is currently solely controlled by Impilo.
KKR is headquartered in the United States while Impilo and Immedica Pharma AB are headquartered in Sweden.
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111